QGRD vs ABUS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while QGRD counters with relative strength in Momentum & Technical. Fundamentally, QGRD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, QGRD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (28th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | QGRD | ABUS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $627.0M | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | ABUS |
| Forward P/E Ratio Valuation | N/M | 10.2x | Lower Multiple | ABUS |
| Revenue Growth (YoY) Growth | N/A | -43.5% | Higher Growth | ABUS |
| Operating Margin (TTM) Profitability | N/A | 80.1% | Higher Margin | ABUS |
| Net Profit Margin Profitability | N/A | 121.2% | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | N/A | 269.6% | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 54% ($24โ$31) | 28% ($4โ$5) | Stronger Trend | QGRD |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 21% Vol | 1.20ฮฒ ยท 51% Vol | Lower Realized Risk | QGRD |
| Unified Institutional Score Composite Signal | 54.7 / 100 (HOLD) | 56.3 / 100 (HOLD) | Higher Composite | ABUS |